Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Minimal Residual Disease 'Coming Soon' As An Approval Endpoint, Celgene Says

Executive Summary

Celgene's ASH briefing notes 'unprecedented' MRD-negative data in Phase I study in multiple myeloma development program for CAR-T therapy bb2121; firm sees potential opportunity for the marker to pave way for approval in earlier-line settings of the disease.

Advertisement

Related Content

City Of Hope's Joseph Alvarnas On CAR-T Real-World Use, Reimbursement
Janssen Exec On Speeding Earlier Myeloma Interventions To Market With Key Biomarker
FDA Grants Blincyto Accelerated Approval Based On MRD Response Endpoint
Amgen Will Try To Convince ODAC Of Minimal Disease Endpoint To Show Blincyto's Efficacy
Supplemental Oncology Approvals: 'Reverse Accelerated Approval,' Not Lowering The Bar
Cancer Trial Endpoints: Minimal Residual Disease Eyed As Surrogate

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS122141

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel